β¨ Medicine Approvals and Drug Prohibition
NEW ZEALAND GAZETTE
No. 161
4476
Product:
Zyprexa Zydis
Active Ingredient:
Olanzapine 10mg
Dosage Form:
Wafer
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturer:
Scherer DDS Limited, Blagrove, Swindon, Wiltshire, England
Product:
Zyprexa Zydis
Active Ingredient:
Olanzapine 15mg
Dosage Form:
Wafer
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturer:
Scherer DDS Limited, Blagrove, Swindon, Wiltshire, England
Product:
Zyprexa Zydis
Active Ingredient:
Olanzapine 20mg
Dosage Form:
Wafer
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturer:
Scherer DDS Limited, Blagrove, Swindon, Wiltshire, England
Product:
Zyprexa Zydis
Active Ingredient:
Olanzapine 5mg
Dosage Form:
Wafer
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturer:
Scherer DDS Limited, Blagrove, Swindon, Wiltshire, England
Product:
Zyprexa
Active Ingredient:
Olanzapine 10mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturers:
Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire, England
Lilly del Caribe, Inc., Carolina, Puerto Rico
Product:
Zyprexa
Active Ingredient:
Olanzapine 2.5mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturers:
Eli Lilly and Company Limited, Basingstoke, Hampshire, England
Lilly del Caribe, Inc., Carolina, Puerto Rico
Product:
Zyprexa
Active Ingredient:
Olanzapine 5mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturers:
Eli Lilly and Company Limited, Basingstoke, Hampshire, England
Lilly del Caribe, Inc., Carolina, Puerto Rico
Product:
Zyprexa
Active Ingredient:
Olanzapine 7.5mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Eli Lilly and Company (NZ) Limited
Manufacturers:
Eli Lilly and Company Limited, Basingstoke, Hampshire, England
Lilly del Caribe, Inc., Carolina, Puerto Rico
Dated this 24th day of November 2003.
DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).
go7813
Misuse of Drugs Act 1975
Prohibition of the Prescribing of Controlled Drugs
Pursuant to section 23 (1) (a) of the Misuse of Drugs Act 1975, I, Annette King, Minister of Health, on the recommendation of the Medical Council of New Zealand,
hereby prohibit the prescribing of Class B and Class C controlled drugs by
Dr Malcolm Paul Lay, medical practitioner of Oamaru.
Dated at Wellington this 24th day of November 2003.
ANNETTE KING, Minister of Health.
go7876
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2003, No 161
Gazette.govt.nz —
NZ Gazette 2003, No 161
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of Changed Medicines
(continued from previous page)
π₯ Health & Social Welfare24 November 2003
Medicines Act 1981, Changed medicines, Zyprexa Zydis, Zyprexa, Olanzapine
- DON MATHESON, Deputy Director-General, Public Health
π₯ Prohibition of Prescribing Controlled Drugs
π₯ Health & Social Welfare24 November 2003
Misuse of Drugs Act 1975, Controlled drugs, Prescribing prohibition, Medical practitioner
- Malcolm Paul Lay (Doctor), Prohibited from prescribing Class B and C controlled drugs
- ANNETTE KING, Minister of Health